Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer.
Quintero-Aldana G, Jorge M, Grande C, Salgado M, Gallardo E, Varela S, López C, Villanueva MJ, Fernández A, Alvarez E, González P, Castellanos J, Casal J, López R, Campos Balea B. Quintero-Aldana G, et al. Among authors: grande c. Cancer Chemother Pharmacol. 2015 Oct;76(4):731-7. doi: 10.1007/s00280-015-2839-z. Epub 2015 Aug 5. Cancer Chemother Pharmacol. 2015. PMID: 26242221 Clinical Trial.
Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group.
León L, Cueva-Banuelos JF, Huidobro G, Fírvida JL, Amenedo M, Lázaro M, Romero C, Estévez SV, Barón FJ, Grande C, García Mata J, González A, Castellanos J, Gómez A, Caeiro M, Rodríguez MR, Casal J; Galician Lung Cancer Group. León L, et al. Among authors: grande c. Lung Cancer. 2003 May;40(2):215-20. doi: 10.1016/s0169-5002(03)00030-8. Lung Cancer. 2003. PMID: 12711124
Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02).
Vázquez S, Huidobro G, Amenedo M, Fírvida JL, León L, Lázaro M, Grande C, Mel JR, Ramos M, Salgado M, Casal J. Vázquez S, et al. Among authors: grande c. Anticancer Drugs. 2007 Nov;18(10):1201-6. doi: 10.1097/CAD.0b013e328273bbce. Anticancer Drugs. 2007. PMID: 17893521 Clinical Trial.
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Roca JM, Alonso V, Pericay C, Escudero P, Salud A, Losa F, López LJ, Guasch I, Méndez M, Quintero-Aldana G, Grande C, Vicente P, Arrivi A, Martin C, Moreno I, García P, Antón I, Constenla M, Yubero A, Cirera L; ACROSS Cooperative Group. Roca JM, et al. Among authors: grande c. Chemotherapy. 2010;56(2):142-6. doi: 10.1159/000313527. Epub 2010 Apr 21. Chemotherapy. 2010. PMID: 20407241 Clinical Trial.
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).
Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas JM, García D, Brunet S, Alonso N, Barba P, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernández-Rivas JÁ, Bernal T. Ribera JM, et al. Among authors: grande c. Cancer. 2013 May 1;119(9):1660-8. doi: 10.1002/cncr.27918. Epub 2013 Jan 29. Cancer. 2013. PMID: 23361927 Free article. Clinical Trial.
363 results